BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy. On September 6, BridgeBio Pharma announced that its investigational, orally-administered therapy, called encaleret, demonstrated parathyroid hormone/PTH-independent normalization of blood and urine calcium in patients with post-surgical hypoparathyroidism.

These positive findings from a Phase 2 proof-of-concept study were presented in an oral presentation at the American Society for Bone and Mineral Research/ASBMR Annual Meeting 2025. The Phase 2 study was designed to evaluate the PTH-independent effects of encaleret on renal calcium handling in 10 participants with post-surgical hypoparathyroidism.

BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism

Participants were administered encaleret at 162 mg twice daily for up to 5 days. Calcitriol, which is a conventional therapy component, was stopped one day before the first dose of encaleret. Key results showed that encaleret treatment led to a rapid and sustained reduction in fractional excretion of calcium in 9 participants

BridgeBio Pharma Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.